Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zolmitriptan transdermal - Zosano Pharma

Next Previous
Drug Profile

Zolmitriptan transdermal - Zosano Pharma

Alternative Names: ADAM-Zolmitriptan; C213 - Zosano Pharma; M 207; Qtrypta; Triptan microneedle patch - Zosano Pharma; Triptan patch - Zosano Pharma; Triptan transdermal - Zosano Pharma; Zolmitriptan Intracutaneous Microneedle System; ZP triptan -Zosano Pharma; ZP-Zolmitriptan; ZP-Zolmitriptan Intracutaneous Microneedle System

Latest Information Update: 20 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zosano Pharma
  • Class Analgesics; Antimigraines; Indoles; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Cluster headache; Migraine

Most Recent Events

  • 18 Dec 2023 Emergex plans submission of Zosano’s epidermal migraine treatment patch NDA for potential marketing authorization to US FDA
  • 18 Dec 2023 Zosano Pharma transferred ownership, as of May 2023, Microneedle Array Patch (MAP) epidermal drug delivery system to Emergex
  • 09 Jun 2022 Zosano Pharma prematurely terminates a phase II/III ATAC trial for Cluster headache in USA (Transdermal) due to several trial sites being closed making enrollment difficult before June 2022 (NCT04066023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top